Vaibhav Sahai, MBBS, MS
Department of Internal Medicine
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Manage Your Profile
Qualifications
-
Chief FellowNorthwestern University, Internal Medicine - Hematology and Oncology, Evanston, United States
2012 - 2013
Chief Fellow
-
FellowNorthwestern University, Internal Medicine - Hematology and Oncology, Evanston, United States
2010 - 2012
Clinical Fellowship
-
ResidentUniversity of Pittsburgh Medical Center, Internal Medicine, Pittsburgh, United States
2007 - 2010
Residency
-
Postdoctoral FellowHarvard Medical School, Radiology, Boston, United States
2006 - 2007
Postdoctoral Fellowship
-
DiplomaBioinformatics Institute of India Noida, Medical Informatics, Noida, Noida, India, India
2004 - 2005
Other
-
MSHarvard School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, United States
2005 - 2006
-
MB BSGovernment Medical College, One Circular Road, Amritsar, Punjab, India, 143001, India
1998 - 2004
Center Memberships
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
Research Overview
The focus of my research lies in experimental therapeutics in pancreaticobiliary cancers via a molecular-based approach in the laboratory. As the Lindsay Olson Pancreatic Cancer Research Professor and Section Head of Gastrointestinal Oncology in the Division of Hematology and Oncology, I am privileged to see patients within the multidisciplinary pancreatic and liver tumor programs. As a tenured clinical and translational researcher, I specialize in the design, implementation, and execution of investigator-initiated and sponsored phase 1/2 clinical trials to investigate novel compounds in patients with pancreas and biliary cancers based on pre-clinical investigation conducted either in my lab or as team science projects. As the Director of Pancreaticobiliary biobanks at the Rogel Cancer Center my translational lab generates and uses organoid models for the therapeutic investigation of novel compounds in pancreaticobiliary cancers. Additionally, I have an imaging lab with focus on imaging software development and research in morphomics and radiomics in pancreaticobiliary cancers. As the Founding Director of the Tumor Response Assessment Core (TRAC) my lab provides standardized, precision imaging metrics for patients enrolled on clinical trials at the Rogel Cancer Center.
Recent Publications
-
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. Clin Cancer Res, 2026 Jul 23;Journal ArticleA phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02.
DOI:10.1158/1078-0432.CCR-25-1114 PMID: 42489677 -
Shah P, Peersen A, Sahai V, Mahipal A, Naleid N, Borad M, Bekaii-Saab T, Sonbol MB, Majeed U, Babiker HM, O'Donnell CDJ, Malla M, Gupta G, Conboy CB, Fonkoua LK, Washburn LA, Halfdanarson TR, Peterson N, McWilliams RR, Carr RM, Graham RP, Starlinger P, Smoot R, Warner S, Ilyas SL, Gores GJ, Roberts L, Heimbach J, Ou F-S, Tran NH. JCO Precis Oncol, 2026 Jul; 10 (7): e2501156Journal ArticleLong-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.
DOI:10.1200/PO-25-01156 PMID: 42430699 -
Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Qiao Y, Chinnaiyan AM. 2026 Jun 21; bioRxiv,PreprintA Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer
DOI:10.64898/2026.06.15.732391 -
Kelley RK, Cleary JM, Sahai V, Baretti M, Bridgewater J, Daniel C, Gliser C, Abou-Alfa GK. The Oncologist, 2026 Jun 24; 31 (Supplement_1): oyag205.036Journal Article35A phase 1/2 trial investigating ivosidenib plus nivolumab and ipilimumab in patients with previously treated mIDH1 CCA
DOI:10.1093/oncolo/oyag205.036 PMID: PMC13287888 -
Shroff RT, Rimassa L, Valle JW, Gunchick V, Gharbi H, Robert R, Sahai V. The Oncologist, 2026 Jun 24; 31 (Supplement_1): oyag205.054Journal Article53Treatment outcomes of patients with mIDH1 cholangiocarcinoma in the United States
DOI:10.1093/oncolo/oyag205.054 PMID: PMC13287848 -
Bao YL, Guo Y, de Castria TB, Boland PM, Toegel EB, Fishel M, Cavnar MJ, Fountzilas C, Chan CHF, Rehman M, Salhia B, Gage MM, Hatoum H, Rounbehler RJ, Churchman ML, Yang W, Sahai V, Malla M, Manne U, Manne A. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 4194 - 4194.Journal ArticleMUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.
DOI:10.1200/jco.2026.44.16_suppl.4194 -
Henstridge A, Sahai V, Peterson N, Machicado JD, Kwon R, Schulman AR, Wamsteker E-J, Philips GM, Menees SB, Xia JY, Hogenson T, Shi J, Frankel T, Bednar F, Di Magliano MP, Lyssiotis CA, Truty MJ, Fernandez-Zapico ME, Carpenter E. Gastroenterology, 2026 May 7; 170 (6): s - 2850.Journal Article296b LONGITUDINAL ANALYSIS OF MATCHED PATIENT BIOSPECIMENS REVEALS NEURAL REPROGRAMMING OF CANCER-ASSOCIATED FIBROBLASTS FOLLOWING CHEMOTHERAPY IN PANCREATIC DUCTAL ADENOCARCINOMA
DOI:10.1016/s0016-5085(26)06741-7 -
Li C, Ke F, Zhao H, Mao S, Djibo M, Huang L, He M, Wang M, Wen H, Liu Z, Yu Z, Qi Z, Xavier AR, Nenwani M, Wen B, Peterson N, Sahai V, Nagrath D, Lucas CL, Wymann MP, Gao W, Fong L, Sun D. Nat Cancer, 2026 Apr 28;Journal ArticleDual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.
DOI:10.1038/s43018-026-01158-7 PMID: 42049931
